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842 Papp et alResults: At week 28, the proportions of patients randomized to tofacitinib 5 and 10 mg BID achieving 75%
or greater reduction in Psoriasis Area and Severity Index score from baseline were 55.6% and 68.8%, and
achieving Physician Global Assessment of clear or almost clear were 54.7% and 65.9%. Efficacy was
maintained in most patients through 24 months. Serious adverse events and discontinuations because of
adverse events were reported in less than 11% of patients over 33 months of tofacitinib exposure.Limitations: There was no dose comparison beyond week 52.Conclusions: Oral tofacitinib demonstrated sustained efficacy in patients with psoriasis through 2 years,
with 10 mg BID providing greater efficacy than 5 mg BID. No unexpected safety findings were observed. ( J
Am Acad Dermatol 2016;74:841-50.)
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tofacitinib.CAPSULE SUMMARY
d Tofacitinib is an oral Janus kinase
inhibitor being investigated for psoriasis.
Short-term efficacy has previously been
demonstrated for moderate to severe
psoriasis.
d We show maintenance of tofacitinib
efficacy through 2 years, with no
unexpected safety findings.
d This supports the continued evaluation
of tofacitinib as a potential, long-term,
oral treatment option for psoriasis.Clinical disease control for
moderate to severe chronic
plaque psoriasis typically
requires continuous, long-
term treatment.1 Although
several treatment options
are available, a substantial
proportion of patients with
psoriasis are not receiving
treatment or are under-
treated, because of long-
term safety concerns, poor
tolerability, failure to achieve
or maintain treatment goals,
patient preference/tolera-
bility for administration
route, cost of medication, and/or access and reim-
bursement issues.2-5
Tofacitinib is an oral Janus kinase inhibitor that is
being investigated for psoriasis. Two phase-III
studies (Oral-treatment Psoriasis Trial [OPT ] Pivotal
1 and 2) have demonstrated efficacy and safety of
continuous tofacitinib treatment versus placebo over
16weeks.6 Herewe report the long-term efficacy and
safety of tofacitinib, comprising data from the Pivotal
studies pooled with interim data from an ongoing
long-term extension (LTE) study that enrolled
patients who had participated in the Pivotal studies.
Efficacy was compared between tofacitinib dosed
5 or 10 mg twice daily (BID) up to week 28, and
maintenance of response was assessed up to 2 years.
Long-term safety was assessed as of the interim LTE
data cut-off (April 4, 2014).
METHODS
Patients
Patient criteria for the Pivotal studies are
described elsewhere.6 Briefly, patients were aged
18 years or older with a diagnosis of plaque-type
psoriasis for 12 months or longer before firststudy drug dose, had a
Psoriasis Area and Severity
Index (PASI) score 12 or
higher, had Physician
Global Assessment (PGA) of
moderate or severe (5-point
scale: 0 = clear, 4 = severe),
and had 10% or more
affected body surface area.
Key exclusion criteria
included recent infections,
current malignancy or his-
tory of malignancies (except
for adequately treated or
excised basal/squamous cell
carcinoma or cervical carci-noma in situ), and history of untreated or inade-
quately treated latent or active Mycobacterium
tuberculosis infection.Study design
The study designs for OPT Pivotal 1
(NCT01276639) and OPT Pivotal 2 (NCT01309737)
are described elsewhere.6 Both were phase-III, multi-
site, randomized, double-blind clinical studies.
Patients were randomized 2:2:1 to tofacitinib 5 mg,
10 mg, or placebo BID. At week 16, all placebo
patients were rerandomized to tofacitinib and
followed up to 52 weeks. All patients who
participated in a Pivotal study for 12 weeks or longer
were eligible for enrollment into the open-label LTE
study (NCT01163253). Patients who did not
achieve either 75% or greater reduction in PASI
score from baseline (PASI75) or a PGA of clear or
almost clear (PGA response) at week 28 in the
Pivotal studies were protocol-mandated to be
withdrawn, with the option to enroll into the LTE
study (Fig 1).
Upon LTE study enrollment, all patients received
tofacitinib 10 mg BID for 3 months. After 3 months,
Abbreviations used:
AE: adverse event
BID: twice daily
CI: confidence interval
HZ: herpes zoster
IR: incidence rate
LTE: long-term extension
NMSC: nonmelanoma skin cancer
OPT: Oral-treatment Psoriasis Trial
PASI: Psoriasis Area and Severity Index
PASI75: 75% or greater reduction in Psoriasis Area
and Severity Index score from baseline
PASI90: 90% or greater reduction in Psoriasis Area
and Severity Index score from baseline
PGA: Physician Global Assessment
SAE: serious adverse event
UV: ultraviolet
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(every 3 months) to tofacitinib 5 or 10 mg BID, based
on safety or efficacy.
All studies were conducted in compliance with
the Declaration of Helsinki and International
Conference on Harmonisation Good Clinical
Practice Guidelines and were approved by the
institutional review boards and/or independent
ethics committees at each investigational center. All
patients provided written, informed consent.
Efficacy assessments
Efficacy was assessed at scheduled visits up to
2 years across the Pivotal and LTE studies for all
patients who were randomized and treated with
tofacitinib in the Pivotal studies, and included the
proportion of patients achieving a PGA response;
proportion achieving PASI75; proportion achieving
90% or greater reduction in PASI score from baseline
(PASI90); and change from baseline in PASI score.
Safety assessments
Adverse events (AEs), serious AEs (SAEs), and
discontinuations because of AEs were reported
for all patients from the first day of tofacitinib
exposure. Safety events of special interest
included: serious infections, herpes zoster (HZ),
opportunistic infections (including tuberculosis),
malignancies (excluding nonmelanoma skin cancer
[NMSC]), NMSC, major adverse cardiovascular
events (adjudicated by a sponsor-independent,
external committee of experts), and gastrointestinal
perforations. Clinical laboratory tests, vital sign
assessments, physical examinations, and 12-lead
electrocardiograms were performed at selected
visits.Statistical analyses
Data were pooled across the 2 Pivotal studies
including additional long-term data for these patients
from the LTE, using an interim data-cut of April 4,
2014 (study ongoing; database unlocked). Data are
reported continuously for each patient, regardless of
whether they were in a Pivotal study or continuing in
the LTE, and all time points are referenced from the
first day of the Pivotal studies.
The efficacy analysis set included all patients who
were initially randomized and received 1 or more
doses of tofacitinib in a Pivotal study. Efficacy data
are reported at visits through 2 years across the
Pivotal and LTE studies; the relatively small number
of patients after 2 years precluded meaningful
analysis beyond this time point. Efficacy data
through week 28 are presented by treatment group
based on randomization in the Pivotal studies, when
most patients were still receiving their initial random-
ization dose. After week 28 a single group is
presented comprising patients receiving all
tofacitinib doses. Patients initially randomized to
placebo were not included in the efficacy analyses
presented. Missing data were handled using last
observation carried forward. Maintenance of efficacy
was compared by treatment group from weeks 16 to
52 using data pooled from the Pivotal studies
(excluding LTE data).
The safety analysis set included all patients who
received 1 or more doses of tofacitinib, including
those who were rerandomized from placebo
to tofacitinib at week 16, and all events are
reported through April 4, 2014. For patients who
advanced from placebo to tofacitinib a new baseline
was established, with the first day of tofacitinib
treatment considered day 1. To allow comparison
of safety events between tofacitinib doses, data are
presented for exposure in the Pivotal studies
(weeks 0-52; excluding LTE data) based on received
dose.
Data are also reported for total tofacitinib expo-
sure from the first day of exposure in the Pivotal
studies through April 2014 in the LTE (33 months), to
assess incidence of AEs over the longest exposure
period possible. Total tofacitinib exposure data are
presented for patients who received tofacitinib
10 mg BID for 80% or more of their study duration
(10 mg BID group) and for all pooled patients
regardless of tofacitinib dose. Incidence rates (IRs)
and 95% confidence intervals (CIs) for safety
events of special interest were calculated using
person-time data adjusted for exposure (patients
with event/100 patient-years).
Fig 1. Study design. *Patients included in the safety analysis from first day of exposure; not
included in the efficacy analysis. yPatients not achieving$75% reduction tofacitinib in Psoriasis
Area and Severity Index score from baseline or Physician Global Assessment response at
week 28. UThree patients deviated from the study protocol and were enrolled into the
long-term extension study after\12 weeks participation in a Pivotal study. BID, Twice daily;
LTE, long-term extension; M, month; N, number; W, week.
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Patients
In the OPT Pivotal studies 1859 patients were
randomized and received treatment. Overall, 1021
(54.9%)patients completedOPTPivotal 1 or 2 through
week 52, 1409 patients enrolled into the LTE study
and, at the data-cut, 990 patients were still receiving
tofacitinib in the LTE (Figs 1 and 2). Mean total daily
dose beyond month 7 (week 28) to month 24 (data
presented pooled across doses) was 17.9 mg.
Demographics and baseline disease characteristics
were similar across treatment groups (Table I).
Efficacy
At week 16, significantly more patients achieved
PASI75 andPGA responsewith tofacitinib 5 and10mg
BID versus placebo, as previously reported.6 From
week 16 to 28 the proportion of patients achieving
PASI75 increased further with both tofacitinib doses;
at week 28, a greater proportion of patients initially
randomized to tofacitinib 10mg BID achieved PASI75versus 5 mg BID (68.8% vs 55.6%, respectively)
(Fig 3, A). Of patients who achieved PASI75 at week
16 with tofacitinib 5 and 10 mg BID, 74.1% and
79.4%, respectively, maintained response through
week 52 in the Pivotal studies (Fig 4, A). PASI75
was also maintained in most patients with all
tofacitinib doses through month 24 (Fig 3, A).
Similar patterns of efficacy response and mainten-
ance were observed with PASI90 (Fig 3, B, and
Fig 4, B) and change from baseline in PASI score
(Fig 3, C ).
PGA response rates increased from week 16 to 28
for patients initially randomized to tofacitinib 5 and
10 mg BID, and at week 28 were 54.7% and 65.9%,
respectively (Fig 3, D). Of patients who achieved a
PGA response at week 16 with tofacitinib
5 and 10 mg BID, 62.0% and 71.6%, respectively,
maintained their response through week 52 in the
Pivotal studies (Fig 4, C ). PGA responses were
maintained in most patients through month 24
(Fig 3, D).
Fig 2. Patient disposition: through week 52 in the Pivotal studies (A) and through April 2014 in
the long-term extension (LTE) study (B). *Causes of discontinuations up to week 16 have
previously been reported.6 yPatients not achieving $75% reduction in Psoriasis Area and
Severity Index score from baseline or Physician Global Assessment response at week 28 were
protocol-mandated to be withdrawn from the study but had the option to enroll into the LTE
study at this point. zPatients who completed $12 weeks in a Pivotal study were eligible to
enroll in the LTE study. AE, Adverse event; BID, twice daily.
Table I. Patient demographics and baseline disease characteristics, according to initially randomized treatment
group (full analysis set)
Tofacitinib 5 mg BID
N = 745
Tofacitinib 10 mg BID
N = 741
Placebo
N = 373
Age,* y (range) 46.0 (18.0-79.0) 45.0 (18.0-82.0) 45.0 (18.0-75.0)
Male, n (%) 529 (71.0) 518 (69.9) 244 (65.4)
Weight,* kg (range) 85.5 (40.8-218.6) 86.0 (38.6-175.0) 86.0 (42.0-188.2)
Race, n (%)
White 611 (82.0) 610 (82.3) 312 (83.6)
Black 21 (2.8) 17 (2.3) 8 (2.1)
Asian 71 (9.5) 74 (10.0) 33 (8.8)
Other 42 (5.6) 40 (5.4) 20 (5.4)
PASI score* (range) 20.0 (9.5-60.9) 20.0 (12.0-66.0) 19.8 (9.6-54.8)
PGA, n (%)
Mild 2 (0.3) 1 (0.1) 1 (0.3)
Moderate 635 (85.2) 631 (85.2) 327 (87.7)
Severe 108 (14.5) 109 (14.7) 45 (12.1)
BID, Twice daily; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment.
*Data are median values.
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A B
C D
Fig 3. Psoriasis. Proportion of patients achieving:$75% (A) or$90% (B) reduction in Psoriasis
Area and Severity Index (PASI) score from baseline response. C, Change from baseline in PASI
score. Physician Global Assessment response of clear or almost clear (full analysis set, last
observation carried forward) (D). *Treatment groups are presented according to the initially
randomized dose at the start of the Pivotal studies. yFrom week 40 to month 24 data are
presented pooled across all tofacitinib doses. Dose comparisons are made through week 28
(dashed line). BID, Twice daily; PASI75, 75% or greater reduction in Psoriasis Area and Severity
Index score from baseline; PASI90, 90% or greater reduction in Psoriasis Area and Severity
Index score from baseline; PGA, Physician Global Assessment; SE, standard error.
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To allow dose comparisons, safety events through
week 52 in the Pivotal studies are reported for 886
(616.6 patient-years) and 884 (660.0 patient-years)
patients who received tofacitinib 5 and 10 mg BID,
respectively. Rates of SAEs and discontinuationsbecause of AEs were low and similar between
tofacitinib doses in the Pivotal studies (\6.0%)
(Table II). The most common AEs were naso-
pharyngitis and upper respiratory tract infection
(Table II). Deaths occurred in 4 patients receiving
tofacitinib 5 mg BID (esophageal carcinoma,
Fig 4. Psoriasis. Proportion of patients maintaining
efficacy between week 16 and 52 in the Pivotal
studies (among patients with a week 16 response; full
analysis set) for: $75 (A) or $90% (B) reduction in
Psoriasis Area and Severity Index score from baseline
=
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[n=2]) and 1 receiving 10 mg BID (cardiac arrest).
IRs for safety events of special interest were low for
both doses through week 52 (Table II). Although a
dose-response was observed for serious infections,
HZ and NMSC, the 95% CIs for each IR overlapped
and the IR difference was small between dose
groups; no dose response was observed for
malignancies (excluding NMSC).
Safety events are also reported for the total
tofacitinib exposure (first day of tofacitinib exposure
in Pivotal studies through April 2014 in the LTE),
to describe the longer-term safety profile of
tofacitinib. This included data from 1807 patients
(2704.8 patient-years) in total (all tofacitinib doses)
and 879 patients (1284.7 patient-years) in the
tofacitinib 10 mg BID group (10 mg BID for $80%
of the study duration); 502 patients in total and
237 patients in the 10 mg BID LTE group received
tofacitinib for more than 2 years. Over 33 months,
10.1% of patients experienced SAEs and 10.7% of
patients discontinued because of AEs (Table II). The
most common AEs remained nasopharyngitis and
upper respiratory tract infection (Table II). As
expected, the number and percentage of reported
AEs increased with longer exposure. However, with
the exception of HZ, exposure-adjusted IRs for safety
events of special interest were comparable between
the total tofacitinib exposure and the first 52 weeks
(Table II), suggesting no increased risk of these
events over time. The IRs for HZ were higher for the
total tofacitinib exposure versus the first 52 weeks,
although 95% CIs overlapped between time periods.
Most HZ cases (59/67 [88.1%]) resolved without
complications; 4 cases were classified as SAEs
(leading to discontinuation) and 5 cases of
postherpetic neuralgia were reported.
A total of 10 (0.6%) deaths (within 30 days of last
study drug dose) were reported for the total
tofacitinib exposure, with an IR of 0.37 (95% CI
0.18-0.68). Further to the 5 deaths discussed above,
causes of death were pancreatic carcinoma, cardiac
arrest, acute respiratory death syndrome, road traffic
accident, and metastatic lung cancer. One additional
death (road traffic accident) occurred with aresponse; and Physician Global Assessment response (C).
BID, Twice daily; PASI75, 75% or greater reduction in
Psoriasis Area and Severity Index score from baseline;
PASI90, 90% or greater reduction in Psoriasis Area and
Severity Index score from baseline; PGA, Physician Global
Assessment.
Table II. Summary of treatment-emergent adverse events (all cause; safety analysis set)
Pivotal study wk 0-52* Total tofacitinib exposurey
Tofacitinib
5 mg BID
N = 886
Tofacitinib
10 mg BID
N = 884
Tofacitinib
10 mg BIDz
N = 879
Tofacitinib
all doses
N = 1807
Total patient exposure, patient-years 616.63 659.96 1284.69 2704.75
Duration of exposure, d, median (range) 253 (1-393) 345.5 (1-393) 548 (1-1016) 602 (1-1026)
Patients with $1 AE, n (%) 567 (64.0) 595 (67.3) 689 (78.4) 1414 (78.3)
AEs leading to discontinuation, n (%) 46 (5.2) 47 (5.3) 99 (11.3) 194 (10.7)
SAEs,x n (%) 46 (5.2) 48 (5.4) 89 (10.1) 183 (10.1)
Most common AEs, n (%); reported in $5% of patients in any group
Nasopharyngitis 94 (10.6) 116 (13.1) 166 (18.9) 340 (18.8)
Upper respiratory tract infection 66 (7.4) 73 (8.3) 119 (13.5) 227 (12.6)
Blood creatine phosphokinase increased 47 (5.3) 76 (8.6) 106 (12.1) 213 (11.8)
Headache 55 (6.2) 55 (6.2) 70 (8.0) 157 (8.7)
Hypercholesterolemia 42 (4.7) 50 (5.7) 66 (7.5) 126 (7.0)
Arthralgia 29 (3.3) 31 (3.5) 51 (5.8) 107 (5.9)
Urinary tract infection 24 (2.7) 22 (2.5) 42 (4.8) 93 (5.1)
Diarrhea 36 (4.1) 31 (3.5) 39 (4.4) 93 (5.1)
Hyperlipidemia 20 (2.3) 29 (3.3) 45 (5.1) 88 (4.9)
Hypertension 24 (2.7) 21 (2.4) 39 (4.4) 86 (4.8)
Influenza 10 (1.1) 26 (2.9) 48 (5.5) 72 (4.0)
AEs of special interest, n [%], IR (patients with event/100 patient-years; 95% CI)
Serious infections// 11 [1.2]
1.78 (0.89-3.19)
18 [2.0]
2.73 (1.62-4.32)
27 [3.1]
2.10 (1.39-3.06)
52 [2.9]
1.93 (1.44-2.53)
Herpes zoster (serious and nonserious){ 7 [0.8]
1.14 (0.46-2.35)
13 [1.5]
1.98 (1.06-3.39)
34 [3.9]
2.70 (1.87-3.78)
67 [3.7]
2.53 (1.96-3.21)
Opportunistic infection 2 [0.2]
0.32 (0.04-1.17)
0 [0.0]
0.00
1 [0.1]
0.08 (0.00-0.43)
8 [0.4]
0.30 (0.13-0.58)
Malignancies (excluding NMSC) 9 [1.0]
1.46 (0.67-2.77)
4 [0.5]
0.61 (0.17-1.55)
12 [1.4]
0.93 (0.48-1.63)
31 [1.7]
1.15 (0.78-1.63)
NMSC 3 [0.3]
0.49 (0.10-1.42)
8 [0.9]
1.22 (0.53-2.40)
13 [1.5]
1.02 (0.54-1.74)
19 [1.1]
0.71 (0.43-1.10)
MACE 3 [0.3]
0.49 (0.10-1.42)
2 [0.2]
0.30 (0.04-1.09)
5 [0.6]
0.39 (0.13-0.91)
11 [0.6]
0.41 (0.20-0.73)
Gastrointestinal perforation 1 [0.1]
0.16 (0.00-0.90)
0 [0.0]
0.00
0 [0.0]
0.00
1 [0.1]
0.04 (0.00-0.21)
AE, Adverse event; BID, twice daily; CI, confidence interval; IR, incidence rate; MACE, major adverse cardiovascular event; n, number of
patients with event; N, number of patients in treatment group; NMSC, nonmelanoma skin cancer; SAE, serious adverse event.
*Weeks 0-52 includes tofacitinib exposure in the Pivotal studies for patients initially randomized to tofacitinib in the Pivotal studies from
week 0-52, and patients who were advanced from placebo to tofacitinib from week 16-52; safety events are reported from the first day of
tofacitinib exposure.
yFrom the first dose of tofacitinib in Oral-treatment Psoriasis Trial Pivotal 1 or 2 or long-term extension, up until the data-cut on April 4, 2014,
among subjects enrolled from Oral-treatment Psoriasis Trial Pivotal 1 or 2.
zFor $80% of their total tofacitinib exposure.
xAEs that resulted in death, were life-threatening, required hospitalization, resulted in significant disability, or resulted in congenital
anomaly/birth defect.
//Any infection (viral, bacterial, and fungal) requiring parenteral antimicrobial therapy or hospitalization, or meeting any other criteria to be
classified as an SAE.
{Serious herpes zoster was reported in 4 (0.2%) patients over the total tofacitinib exposure with all doses.
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tofacitinib.
DISCUSSION
Previous reports in patients with moderate to
severe plaque psoriasis have shown significantlygreater efficacy with short-term (up to 16 weeks)
tofacitinib therapy versus placebo6,7; this
analysis demonstrated maintenance of clinical
response for up to 2 years across the Pivotal and
LTE studies with continuous tofacitinib treatment.
From week 16 to 28 clinical responses increased
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efficacy versus 5 mg BID (;65% vs 55% of patients
achieving PASI75/PGA response). Moreover, most
patients who achieved a PASI75 or PGA response at
week 16 maintained their response through
week 52 in the Pivotal studies. Efficacy was further
maintained, with the overall response rate of ;50%
for PASI75 and PGA, and ;35% for PASI90 at
month 24. The variable long-term dosing in this
study reflects real-life practice, with dose changes
based on clinical patient treatment in response to
efficacy and safety findings.
Current oral treatment options for psoriasis
include the traditional systemics: methotrexate,
cyclosporin, and acitretin; in addition, the small
molecule phosphodiesterase-4 inhibitor apremilast
recently became available in the United States and
European Union.8 Efficacy of tofacitinib compares
favorably with traditional systemic treatments,9-13
with 10 mg BID providing greater efficacy compared
with methotrexate,9,12 and acitretin,11,13 and similar
maintenance of response,9-13 although no head-
to-head studies are available to allow direct
comparisons. In a study of apremilast 30 mg BID,
the proportion of patients achieving PASI75 was
appreciably lower (;30%) than reported here with
tofacitinib (;60%) over 52 weeks. Efficacy was
maintained in a similar proportion of patients with
both treatments through week 52; data beyond
week 52 are not published for apremilast.14 In
addition, a 12-week phase-III study directly
comparing tofacitinib with the biologic therapy
etanercept demonstrated noninferiority of tofacitinib
10 mg BID to etanercept with similar incidence of
safety events; tofacitinib 5 mg BID did not meet
noninferiority criteria versus etanercept.7 Therefore,
tofacitinib may offer a viable alternative to other
psoriasis treatments as it appears to be tolerated
long-term and to have high initial efficacy, with
clinical response maintained over time in most
patients.
Safety findings through week 52 were consistent
with those previously reported in phase-III studies of
tofacitinib for psoriasis with durations of 12 to
56 weeks.6,7,15 No dose-response was observed for
the overall rate of AEs, SAEs, or discontinuations
because of AEs through week 52. The rates of SAEs
and discontinuations because of AEs over 52 weeks
of tofacitinib treatment are similar to that of
apremilast in psoriasis, with infections the most
common AEs.14 Unlike conventional oral treatments
such as methotrexate and cyclosporine,8,12 no
evidence of end-organ toxicity was observed over
time with tofacitinib. Comparison of IRs between the
first 52 weeks’ exposure and total exposure indicatedno increased risk of safety events with increased
tofacitinib duration, with the exception of HZ, which
had a numerically higher IR for the total exposure.
However, most HZ cases resolved without
complications, and safety event monitoring over
longer tofacitinib exposure is continuing. Increased
risk of HZ with tofacitinib treatment has been
reported in patients with psoriasis who are
Japanese, biologic-experienced, older than 65 years,
or have diabetes.16
A recently published analysis of the Clalit Health
Service database including over 500,000 patient-years
of follow-up reported IRs for HZ ranging from
0 to 3.23 events/100 patient-years with various
systemic psoriasis treatments.17 The 95% CIs for
tofacitinib overlapped with those of other treatments
including psoralen and ultraviolet (UV)A, UVB,
cyclosporin, infliximab, andmethotrexate or acitretin
in combination with biologics.17 When looking at
tofacitinib exposure up to 52 weeks in the Pivotal
studies, the IR for HZ with 5 mg BID appeared
similar to IRs reported for methotrexate, etanercept,
adalimumab, psoralen and UVA, and UVB, and the IR
with 10 mg BID appeared similar to cyclosporine,
infliximab, and methotrexate or acitretin with
biologics.17
There are somemethodologic limitations inherent
to studies assessing the long-term efficacy of
treatments, particularly the drop-out of patients
over time. The assumption underlying the last
observation carried forward handling of missing
data values was that efficacy was maintained if
patients remained in the study, which cannot be
verified. Comparing the results across different
studies may be difficult because of different
methodologies used.
In conclusion, tofacitinib 10 mg BID had
greater efficacy than 5 mg BID and efficacy was
sustained for up to 2 years across the Pivotal and
LTE studies in patients with moderate to severe
plaque psoriasis. During the first 52 weeks,
occurrence of AEs, SAEs, and discontinuations
because of AEs were similar between doses.
Generally, IRs for safety events were consistent
between the first 52 weeks and overall tofacitinib
exposure, although incidence of HZ was slightly
higher in the overall exposure group. These data
support the continued evaluation of tofacitinib as
a potential new, long-term, oral treatment option
for plaque psoriasis.
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